Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
Conditions
Interventions
Intervention1: Vortioxetinee: 10 mg OD for one and half month
Control Intervention1: Escitalopram: 10 mg OD for one and half month
Sponsors
Ronakkumar Chandubhai Patel
Eligibility
Inclusion criteria
Inclusion criteria: All patients giving written consent will be taken. Subjects >18 & 2 and <6 on the initial visit will be enrolled in the study.
Exclusion criteria
Exclusion criteria: Current or past comorbid diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, a psychotic disorder not otherwise specified, mood-congruent or mood-incongruent psychotic features, bipolar disorder, alcohol or substance-use disorder, organic mental disorder including dementia, eating disorder, or obsessive compulsive disorder; presence of a seizure disorder; previous treatment with electroconvulsive therapy; currently pregnant/lactating women; and risk of suicide. • All patients with an unclear history of antidepressant treatment. Patients not giving informed consent. Patients scoring =6 on MADRS items number 10 (suicidal thoughts) at screening or baseline, history of non response to an adequate (6 week) trial of three or more antidepressant (with or without mood stabilizers) during the current episode, with imminent risk of suicide or injury to self, others, or property. Besides, patients with current clinically significant neurological, metabolic (including typel diabetes), hepatic, renal, hematological, pulmonary. cardiovascular, gastrointestinal, and/or urological disorder such, as unstable angina, congestive heart failure (uncontrolled), or central nervous system (CNS) infection that would pose a risk to the subject if they were to participate in the study or that might confound the results of the study subjects with human immunodeficiency virus (HIV) seropositivity (or history of seropositivity), history of malignancy, or any chronic incapacitating illness will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of lifeTimepoint: Baseline, 2 weeks, 4 weeks, 6 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reaction of drugsTimepoint: Every 2 week for 6 week | — |
Countries
India
Contacts
Public ContactDr. Ronakkumar Patel
Baba Raghav Das medical college, Gorakhpur
Outcome results
None listed